Cerebellar infarction risk in a mild COVID-19 case

Area of Science:

• Neurology
• Cardiology
• Infectious Diseases

Background:

• Thrombotic events are a frequent complication in patients diagnosed with SARS-COV-2 (COVID-19).
• Patients with pre-existing conditions like heart failure, hypertension, cancer, diabetes, kidney failure, vascular disease, and pulmonary illnesses face a higher risk.
• These thrombotic complications can occur even with anticoagulation therapy, particularly in severe or hospitalized cases.

Observation:

• The study highlights that thrombotic events, including pulmonary thromboembolism, cerebral ischemic stroke, and peripheral artery thrombosis, are significant concerns.
• Notably, some patients with the mentioned comorbidities develop thrombotic events irrespective of the severity of their SARS-COV-2 infection.
• The cerebellum is identified as an uncommon but potential target for these thrombotic events.

Findings:

• Thrombotic events in SARS-COV-2 patients with comorbidities are frequent and can manifest despite anticoagulation treatment.
• Cerebral ischemic stroke and pulmonary thromboembolism are primary thrombotic manifestations.
• The cerebellum is an identified, albeit uncommon, site for thrombotic events in this patient population.

Implications:

• Understanding these thrombotic risks is crucial for managing SARS-COV-2 (COVID-19) patients, especially those with comorbidities.
• The findings underscore the need for vigilant monitoring and potentially adjusted therapeutic strategies to prevent thrombotic complications.
• Further research into the specific mechanisms of thrombotic events, including those affecting the cerebellum, is warranted.